Canagliflozin Appraisal Terminated for Type 2 Diabetes in Youth

NICE Technology Appraisals

Published February 25th, 2026

Detected March 12th, 2026

Summary

NICE has terminated the appraisal of canagliflozin (Invokana) for treating type 2 diabetes in individuals aged 10 to 17 years. The appraisal was terminated because the company failed to provide an evidence submission. NICE will review this decision if a submission is made.

View original document View source feed page

What changed

The National Institute for Health and Care Excellence (NICE) has terminated the technology appraisal for canagliflozin (Invokana) for the treatment of type 2 diabetes in individuals aged 10 to 17 years. This termination occurred because the pharmaceutical company did not submit the required evidence for review, preventing NICE from making a recommendation on its use.

This decision means that canagliflozin will not be recommended by NICE for this specific patient group at this time. Pharmaceutical companies seeking appraisal for new treatments must ensure timely and complete evidence submissions. NICE has indicated that the appraisal may be reopened if the company decides to make a submission in the future.

Source document (simplified)

Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)

Technology appraisal
TA1137
Published:

25 February 2026

Download guidance (PDF)

Overview

NICE is unable to make a recommendation on canagliflozin (Invokana) for treating type 2 diabetes in children and young people 10 to 17 years. This is because the company did not provide an evidence submission.

Last reviewed: 25 February 2026

Next review: We will review this decision if the company decides to make a submission.